Chengdu Easton Biopharmaceuticals Co. Ltd. has described lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of cancer.
Merck KGaA has divulged proteolysis targeting chimeras (PROTACs) compounds comprising an E3 ubiquitin ligase binding agent coupled to methionine aminopeptidase-2 (MNPEP; MetAP2) targeting moiety via a linker reported to be useful for the treatment of cancer, rheumatoid arthritis, psoriasis, osteoporosis, diabetes, obesity, malaria and benign prostatic hyperplasia, among others.
Gilead Sciences Inc. has identified protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Adlai Nortye Pharmaceutical Co. Ltd. has disclosed Wnt signaling inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Radiopharm Theranostics Ltd. has entered into an expanded agreement with Terthera BV under which Terthera will supply Radiopharm with Terbium-161 (Tb-161). The Tb-161 isotope will be linked to a proprietary monoclonal antibody to form RAD-402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression.
Microtubule-associated serine/threonine kinase-like (MASTL) is involved in cell proliferation, migration, and invasion and for that reason is considered a relevant therapeutic target for cancer treatment. At the recent ACS Fall meeting, researchers from Pfizer Inc. presented the discovery and characterization of a series of potent and selective MASTL inhibitors for the treatment of cancer.
KRAS-mutated tumors were once untreatable. In fact, KRAS was something of a poster child for so-called undruggability. Several laboratories are investigating strategies to address other mutations and uses beyond non-small cell lung cancer (NSCLC) and colorectal cancer. If you can't bind KRAS to block it, use a glue or combine multiple weapons. This is the idea behind two new approaches that target cancers caused by this proto-oncogene.
Vivace Therapeutics Inc. has identified transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, polycystic kidney and hepatic fibrosis.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed fused heterocyclic compounds acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis and inflammatory disorders, among others.
RSS
